Cargando…

Economic Impact of Comorbidity burden in Total Ankle Arthroplasty and Ankle Arthrodesis

CATEGORY: Ankle, Ankle Arthritis, Diabetes INTRODUCTION/PURPOSE: Demand for total ankle arthroplasty (TAA) and ankle arthrodesis surgery is increasing. Findings from other orthopaedic populations suggest an increasing comorbidity burden among those planned for surgery, however, data on TAA and ankle...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Jimmy J., Guzman, Javier Z., Chan, Jesse C., Zubizarreta, Nicole, Poeran, Jashvant, Vulcano, Ettore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8696539/
http://dx.doi.org/10.1177/2473011419S00133
_version_ 1784619837051371520
author Chan, Jimmy J.
Guzman, Javier Z.
Chan, Jesse C.
Zubizarreta, Nicole
Poeran, Jashvant
Vulcano, Ettore
author_facet Chan, Jimmy J.
Guzman, Javier Z.
Chan, Jesse C.
Zubizarreta, Nicole
Poeran, Jashvant
Vulcano, Ettore
author_sort Chan, Jimmy J.
collection PubMed
description CATEGORY: Ankle, Ankle Arthritis, Diabetes INTRODUCTION/PURPOSE: Demand for total ankle arthroplasty (TAA) and ankle arthrodesis surgery is increasing. Findings from other orthopaedic populations suggest an increasing comorbidity burden among those planned for surgery, however, data on TAA and ankle arthrodesis is lacking. METHODS: This retrospective cohort study utilized data from the nationwide Premier Healthcare Database (2006-2016) which contains inpatient claims on N=10,085 ankle arthrodesis and N=4,977 TAA procedures. Patients were categorized into Deyo Charlson comorbidity index groups with higher scores representing higher comorbidity burden: 0, 1, 2, =3. Outcomes were cost of hospitalization, length of stay (LOS), total opioid utilization (in oral morphine equivalents), discharge to a skilled nursing facility (SNF) and 30-day readmission. Mixed-effects models estimated associations between Deyo-Charlson comorbidity index and outcomes. We report odds ratios (OR, or % change for continuous outcomes) and 95% confidence intervals (CI). RESULTS: In the TAA group, 64.4% of patients were in Deyo-Charlson category 0 while 24.1%, 7.6%, and 3.9% were in the 1, 2, and =3 Deyo-Charlson categories, respectively; this was 50.3%, 23.2%, 12.4% and 14.1% in the ankle arthrodesis group. The most common comorbidities were obesity, diabetes mellitus and chronic pulmonary disease. After adjustment for relevant covariates, patients in the Deyo-Charlson group =3 (compared to ‘0’) were associated with stepwise effects of 77.1% (CI 70.9%;83.6%) longer LOS and 48.5% (CI 44.0%;53.2%) higher cost of hospitalization with higher odds for admission to a SNF (OR=3.12 CI 2.64;3.70), all P<0.0001. Smaller or non-significant effects of comorbidity burden were seen for opioid utilization and 30 day readmission. These effects were also present but less pronounced in TAA patients. CONCLUSION: Comorbidity burden is particularly increasing among patients undergoing ankle arthrodesis where it is associated with significantly increased resource utilization. Our data demonstrate the potential impact of patient selection, which may be crucial in optimizing preoperative status.
format Online
Article
Text
id pubmed-8696539
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-86965392022-01-28 Economic Impact of Comorbidity burden in Total Ankle Arthroplasty and Ankle Arthrodesis Chan, Jimmy J. Guzman, Javier Z. Chan, Jesse C. Zubizarreta, Nicole Poeran, Jashvant Vulcano, Ettore Foot Ankle Orthop Article CATEGORY: Ankle, Ankle Arthritis, Diabetes INTRODUCTION/PURPOSE: Demand for total ankle arthroplasty (TAA) and ankle arthrodesis surgery is increasing. Findings from other orthopaedic populations suggest an increasing comorbidity burden among those planned for surgery, however, data on TAA and ankle arthrodesis is lacking. METHODS: This retrospective cohort study utilized data from the nationwide Premier Healthcare Database (2006-2016) which contains inpatient claims on N=10,085 ankle arthrodesis and N=4,977 TAA procedures. Patients were categorized into Deyo Charlson comorbidity index groups with higher scores representing higher comorbidity burden: 0, 1, 2, =3. Outcomes were cost of hospitalization, length of stay (LOS), total opioid utilization (in oral morphine equivalents), discharge to a skilled nursing facility (SNF) and 30-day readmission. Mixed-effects models estimated associations between Deyo-Charlson comorbidity index and outcomes. We report odds ratios (OR, or % change for continuous outcomes) and 95% confidence intervals (CI). RESULTS: In the TAA group, 64.4% of patients were in Deyo-Charlson category 0 while 24.1%, 7.6%, and 3.9% were in the 1, 2, and =3 Deyo-Charlson categories, respectively; this was 50.3%, 23.2%, 12.4% and 14.1% in the ankle arthrodesis group. The most common comorbidities were obesity, diabetes mellitus and chronic pulmonary disease. After adjustment for relevant covariates, patients in the Deyo-Charlson group =3 (compared to ‘0’) were associated with stepwise effects of 77.1% (CI 70.9%;83.6%) longer LOS and 48.5% (CI 44.0%;53.2%) higher cost of hospitalization with higher odds for admission to a SNF (OR=3.12 CI 2.64;3.70), all P<0.0001. Smaller or non-significant effects of comorbidity burden were seen for opioid utilization and 30 day readmission. These effects were also present but less pronounced in TAA patients. CONCLUSION: Comorbidity burden is particularly increasing among patients undergoing ankle arthrodesis where it is associated with significantly increased resource utilization. Our data demonstrate the potential impact of patient selection, which may be crucial in optimizing preoperative status. SAGE Publications 2019-10-28 /pmc/articles/PMC8696539/ http://dx.doi.org/10.1177/2473011419S00133 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Article
Chan, Jimmy J.
Guzman, Javier Z.
Chan, Jesse C.
Zubizarreta, Nicole
Poeran, Jashvant
Vulcano, Ettore
Economic Impact of Comorbidity burden in Total Ankle Arthroplasty and Ankle Arthrodesis
title Economic Impact of Comorbidity burden in Total Ankle Arthroplasty and Ankle Arthrodesis
title_full Economic Impact of Comorbidity burden in Total Ankle Arthroplasty and Ankle Arthrodesis
title_fullStr Economic Impact of Comorbidity burden in Total Ankle Arthroplasty and Ankle Arthrodesis
title_full_unstemmed Economic Impact of Comorbidity burden in Total Ankle Arthroplasty and Ankle Arthrodesis
title_short Economic Impact of Comorbidity burden in Total Ankle Arthroplasty and Ankle Arthrodesis
title_sort economic impact of comorbidity burden in total ankle arthroplasty and ankle arthrodesis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8696539/
http://dx.doi.org/10.1177/2473011419S00133
work_keys_str_mv AT chanjimmyj economicimpactofcomorbidityburdenintotalanklearthroplastyandanklearthrodesis
AT guzmanjavierz economicimpactofcomorbidityburdenintotalanklearthroplastyandanklearthrodesis
AT chanjessec economicimpactofcomorbidityburdenintotalanklearthroplastyandanklearthrodesis
AT zubizarretanicole economicimpactofcomorbidityburdenintotalanklearthroplastyandanklearthrodesis
AT poeranjashvant economicimpactofcomorbidityburdenintotalanklearthroplastyandanklearthrodesis
AT vulcanoettore economicimpactofcomorbidityburdenintotalanklearthroplastyandanklearthrodesis